SCHEMBL14426566

SCHEMBL14426566

CN1C(=O)/C(=C/c2ccc(-c3ccc(Cl)cc3)o2)S/C1=N/c1ccc(Cl)c(C(=O)O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 6/20 0.69
▸ ALDH1A1 P00352 5/20 0.69
▸ MAPT P10636 5/20 0.69
▸ MCL1 Q07820 3/20 0.69
▸ NSD2 O96028 1/20 0.69
▸ HPGD P15428 1/20 0.69
▸ PSMB8 P28062 5/20 0.65
▸ MEN1 O00255 7/20 0.56
▸ KMT2A Q03164 7/20 0.56
▸ TDP1 Q9NUW8 4/20 0.56
▸ L3MBTL1 Q9Y468 3/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ PPARG P37231 1/20 0.55
▸ PKM P14618 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ KLKB1 P03952 1/20 0.54
▸ CTSB P07858 1/20 0.54
▸ ELANE P08246 1/20 0.54
▸ CASP3 P42574 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12177768 0.87 PSMB8 (0.84) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL12177594 0.87 PSMB8 (0.70) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL12177593 0.84 PSMB8 (0.78) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL12177429 0.83 PSMB8 (0.65) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL14426564 0.82 PSMB8 (0.92) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL2586820 0.82 PSMB8 (0.92) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL2586823 0.82 PSMB8 (0.92) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL12177333 0.81 PSMB8 (0.62) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL14426563 0.79 PSMB8 (0.75) POLBALDH1A1MAPTMCL1NSD2
SCHEMBL14426551 0.78 PSMB8 (0.84) POLBALDH1A1MAPTPSMB8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070196395-A1 Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-08-23 — — US disclosed
US-20070196395-A1 Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-08-23 — — US disclosed
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-05-03 — — US disclosed
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain LCK, PTPN6, PTPN22 POLB 4376/4885ALDH1A1 4878/4885MAPT 2522/4885
US-20070196395-A1 Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain LCK, PTPN6, PTPN22 POLB 4376/4885ALDH1A1 4878/4885MAPT 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback